Cytosorbents Corporation
CTSO
$1.13
-$0.005-0.44%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.74M | 37.16M | 36.69M | 36.35M | 37.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.74M | 37.16M | 36.69M | 36.35M | 37.07M |
| Cost of Revenue | 14.07M | 13.17M | 13.18M | 13.96M | 14.23M |
| Gross Profit | 23.67M | 23.99M | 23.51M | 22.39M | 22.84M |
| SG&A Expenses | 35.32M | 36.59M | 37.26M | 37.14M | 35.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.11M | 61.37M | 64.20M | 66.83M | 64.82M |
| Operating Income | -21.37M | -24.21M | -27.51M | -30.48M | -27.75M |
| Income Before Tax | -19.48M | -26.34M | -28.35M | -29.32M | -24.53M |
| Income Tax Expenses | -813.70K | -813.70K | -813.70K | -813.70K | -1.09M |
| Earnings from Continuing Operations | -18.67 | -25.53 | -27.54 | -28.51 | -23.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.67M | -25.53M | -27.54M | -28.51M | -23.44M |
| EBIT | -21.37M | -24.21M | -27.51M | -30.48M | -27.75M |
| EBITDA | -19.80M | -22.61M | -25.91M | -29.02M | -26.46M |
| EPS Basic | -0.36 | -0.53 | -0.59 | -0.64 | -0.53 |
| Normalized Basic EPS | -0.23 | -0.33 | -0.37 | -0.40 | -0.34 |
| EPS Diluted | -0.36 | -0.53 | -0.59 | -0.64 | -0.53 |
| Normalized Diluted EPS | -0.23 | -0.33 | -0.37 | -0.40 | -0.34 |
| Average Basic Shares Outstanding | 209.57M | 199.49M | 189.20M | 178.62M | 175.70M |
| Average Diluted Shares Outstanding | 209.57M | 199.49M | 189.20M | 178.62M | 175.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
